A Phase IB Study of Safety, Efficacy and Pharmacokinetic of Intravenously Administered Pelcitoclax (APG-1252) in Patients With Advanced Neuroendocrine Tumor
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 3
- 主要终点
- Safety data
研究概览
简要总结
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w. The preclinical studies have shown that APG-1252 alone achieves complete and persistent tumor regression in multiple tumor xenograft models with a twice weekly or weekly dose-schedule, including SCLC, colon, breast and ALL cancer xenografts; achieves strong synergy with the chemotherapeutic agents, indicating that APG-1252 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252 is intended for the treatment of patients with neuroendocrine tumors. The purpose of the phase 1b study to establish the maximum tolerated dose (MTD), and/or recommended phase 2 dose (RP2D). Preliminary efficacy and pharmacokinetic properties will be aslo evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed neuroendocrine tumors (G1, G2, G3).
- •Locally advanced or metastatic disease for which no standard therapy is judged appropriate by the investigator.
- •Male or non-pregnant, non-lactating female patients age ≥18 years.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤
- •Estimated life span ≥3 months.
- •At least one measurable lesion by RECIST 1.
- •Adequate hematologic and bone marrow functions.
- •Adequate renal and liver function.
- •Adequate cardiac function.
- •Brain metastases with clinically controlled neurologic symptoms.
- •Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential (postmenopausal women must have been amenorrheal for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug.
- •Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).
- •Willingness and ability to comply with study procedures and follow-up examination.
排除标准
- •Neuroendocrine carcinoma (NEC).
- •Received chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or any investigational therapy within 28 days prior to the first dose of study drug; received TKIs within 5 x half-time.
- •Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not recover to < Grade
- •Known bleeding diathesis/disorder.
- •Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within 1 year prior to first dose of study drug.
- •Have active immune thrombocytopenic purpura (ITP), active autoimmune hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).
- •Serious gastrointestinal bleeding within 3 months.
- •Use of therapeutic doses of anti-coagulants is excluded, along with anti-platelet agents; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are permitted.
- •Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
- •Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry.
- •Uncontrolled concurrent illness including, but not limited to: serious uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
- •Prior treatment with Bcl-2/Bcl-xL inhibitors.
- •Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.
研究组 & 干预措施
APG-1252
干预措施: Pelcitoclax (Drug)
结局指标
主要结局
Safety data
时间窗: 24 months
Incidence of adverse events (AEs)
Maximum tolerated dose (MTD) determination
时间窗: 28 days
If ≥ 2/6 patients develop a DLT at any dose level, then the MTD will be assumed to have been exceeded. The dose level immediately below will then be expanded to 6 patients and, if no more than 1/6 patients develop DLT, then this dose will be declared the MTD.
次要结局
- Preliminary Efficacy(24 months)
- Pharmacokinetic(28 days)